The ability of collagen to influence immunotherapy could involve DDR2-signaling since treatment of several murine cancer models with a combination of anti-PD-1 antibody and a DDR2-inhibitor led to an increase in CD8+ T cells and a reduced tumor burden (187). The gene discussed is CD8A; the disease is neoplasm.